What is NAD?

Mice engineered to have low body-wide NAD+ levels exhibit a shortened lifespan and widespread physical decline, which is largely reversed with the NAD+ booster niacin.

Life Biosciences reports preliminary visual-field improvements in two of three glaucoma patients treated with the experimental therapy developed by Dr. David Sinclair’s Harvard team, ER-100.

Transplantation of the cell’s powerhouses (mitochondria) improves heart function by restoring mitophagy (the cellular process that clears damaged mitochondria) in a mouse model of cardiac aging.

NAD+ (nicotinamide adenine dinucleotide) levels were lower among older adults with frailty—an age-related condition associated with increased vulnerability to disability, disease, and death.

A TIME Magazine longevity panel, featuring Harvard’s David Sinclair, explores whether breakthroughs in AI, cellular rejuvenation, and research on sex differences could help today’s children live far longer.

The Harvard geneticist discussed an early human trial, unpublished mouse results, and an AI-assisted search for chemical rejuvenation therapies on the Joe Rogan Experience.

Six proteomics-based aging clocks (age assessments from large-scale analyses of proteins) agreed that patients treated with the AI-designed drug rentosertib appeared younger.

Supplementing chronically stressed mice with L-serine, an amino acid, counters signs of anxiety and diabetes while diverting age-promoting senescent cells within the brain’s fear center.

A new study describes a large cross-species testing system—using species from yeast to mice—to identify promising lifespan-extending drug candidates more efficiently.

Semaglutide extends mouse lifespan and targets signs of aging, such as diminished NAD+, while mimicking the anti-aging effects of caloric restriction (consuming fewer calories).